Department of Medical Pharmacology and Physiology, University of Missouri-Columbia School of Medicine, Columbia, MO 65212, USA.
Biochem Pharmacol. 2012 Oct 15;84(8):1045-54. doi: 10.1016/j.bcp.2012.07.023. Epub 2012 Aug 1.
Sildenafil is a cGMP-specific phosphodiesterase type 5 inhibitor that augments cGMP accumulation following the activation of soluble guanylate cyclase (sGC). In this study, we investigated whether sildenafil promotes the production of the sGC-stimulatory gases, carbon monoxide and nitric oxide, by stimulating the expression of the inducible isoforms of heme oxygenase (HO-1) and nitric oxide synthase (iNOS) in vascular smooth muscle cells (SMCs). Sildenafil increased HO-1 expression and potentiated cytokine-mediated expression of iNOS and NO synthesis by SMCs. The induction of HO-1 was unaffected by the sGC inhibitor 1H-(1,2,4)oxadiazolo[4,3-α]quinozalin-1-one (ODQ) or the protein kinase G inhibitor (8R,9S,11S)-(-)-2-methyl-9-methoxyl-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a-triazadibenzo(a,g)cyclocta9(cde)trinen-1-one (KT 5823). However, the sildenafil-mediated increase in HO-1 promoter activity was abolished by mutating the antioxidant responsive elements in the promoter or by overexpressing a dominant-negative mutant of NF-E2-related factor-2 (Nrf2). Furthermore, the induction of HO-1 by sildenafil was accompanied by an increase in reactive oxygen species (ROS) and blocked by N-acetyl-L-cysteine and rotenone. In contrast, the enhancement of cytokine-stimulated NO synthesis by sildenafil was prevented by ODQ and the protein kinase A inhibitor (9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid hexyl ester (KT 5720) and duplicated by lipophilic analogs of cGMP. In conclusion, these studies demonstrate that sildenafil stimulates the expression of HO-1 and iNOS via the ROS-Nrf2 and sGC-cGMP pathway, respectively. The ability of sildenafil to block the catabolism of cGMP while stimulating the synthesis of sGC-stimulatory gaseous monoxides through the induction of HO-1 and iNOS provides a potent mechanism by which cGMP-dependent vascular actions of this drug are amplified.
西地那非是一种 cGMP 特异性磷酸二酯酶 5 抑制剂,可在可溶性鸟苷酸环化酶 (sGC) 激活后增强 cGMP 的积累。在这项研究中,我们研究了西地那非是否通过刺激血管平滑肌细胞 (SMC) 中诱导型血红素加氧酶 (HO-1) 和一氧化氮合酶 (iNOS) 的表达来促进 sGC 刺激气体一氧化碳和一氧化氮的产生。西地那非增加了 HO-1 的表达,并增强了细胞因子介导的 iNOS 表达和 SMC 中 NO 的合成。HO-1 的诱导不受 sGC 抑制剂 1H-(1,2,4)恶二唑并[4,3-α]喹喔啉-1-酮 (ODQ) 或蛋白激酶 G 抑制剂 [(8R,9S,11S)-(-)-2-甲基-9-甲氧基-9-甲氧基羰基-8-甲基-2,3,9,10-四氢-8,11-环氧-1H,8H,11H-2,7b,11a-三氮杂二苯并(a,g)环辛烷-9(cde)三烯-1-酮 (KT5823)] 的影响。然而,西地那非介导的 HO-1 启动子活性增加被突变启动子中的抗氧化反应元件或过表达 NF-E2 相关因子-2 (Nrf2) 的显性负突变体所消除。此外,西地那非诱导的 HO-1 伴随着活性氧 (ROS) 的增加,并被 N-乙酰-L-半胱氨酸和鱼藤酮阻断。相比之下,西地那非增强细胞因子刺激的 NO 合成被 ODQ 和蛋白激酶 A 抑制剂 (9S,10S,12R)-2,3,9,10,11,12-六氢-10-羟基-9-甲基-1-氧代-9,12-环氧-1H-二吲哚(1,2,3-fg:3',2',1'-kl)吡咯并(3,4-i)(1,6)苯并二氮杂环辛烷-10-羧酸己酯 (KT5720) 阻止,并被 cGMP 的亲脂类似物复制。总之,这些研究表明,西地那非通过 ROS-Nrf2 和 sGC-cGMP 途径分别刺激 HO-1 和 iNOS 的表达。西地那非阻断 cGMP 分解代谢的能力,同时通过诱导 HO-1 和 iNOS 刺激 sGC 刺激的气态单氧化物的合成,为该药物的 cGMP 依赖性血管作用放大提供了一种有效的机制。